What happens when brain tumors return? International study tracks genetic changes behind recurring cancers

by Roberto Molar Candanosa, Jackson Laboratory

edited by Gaby Clark, reviewed by Robert Egan

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add to Preferred Sources

When patients are diagnosed with certain brain tumors, one of the biggest unanswered questions is what happens when the cancer returns. Among those are IDH-mutant gliomas, a group of brain tumors that invariably recur despite advances in treatment.

Now, scientists from The Jackson Laboratory (JAX), Yale University and collaborators across 10 countries report that these gliomas undergo unique genetic changes when they return after treatment.

The findings, published today in Nature, could help researchers understand why these tumors become resistant to therapy and point toward more tailored treatment approaches in the future.

IDH-mutant gliomas are defined by mutations in a gene called isocitrate dehydrogenase (IDH). These tumors primarily affect patients in their 30s and 40s, making them particularly devastating. Although many patients live for years after diagnosis, these tumors almost always recur and eventually stop responding to treatment.

Tracking genetic changes across recurrence

The study drew on data from the international Glioma Longitudinal Analysis (GLASS) Consortium and included 183 patients whose tumors were sampled both before and after recurrence, allowing researchers to directly compare how the cancers changed over time. Researchers analyzed samples collected through more than 500 surgeries spanning North America, Europe, Asia, Australia and South America.

"IDH-mutant gliomas are rare, which makes them challenging to study. Through this international collaboration, we were able to gather enough samples to characterize the most common ways each type of IDH-mutant glioma changes when it recurs," said study author Frederick Varn, a JAX assistant professor who co-led the research.

The unique data set allowed researchers to follow tumors over time and examine how they changed after treatment and recurrence. For example, the chemotherapy drug temozolomide appeared to leave distinct genetic fingerprints in recurrent tumors. This finding highlights how standard treatments may influence the genetic changes tumors acquire as they recur.

Two tumor types take different genetic paths

The most striking differences emerged in how the tumors changed over time despite sharing the same defining IDH mutation. One subtype of IDH-mutant glioma, called oligodendroglioma, tended to acquire new mutations in genes that help drive tumor growth. By contrast, a different subtype, called astrocytoma, was more likely to undergo large-scale chromosomal changes, gaining and losing large stretches of DNA as the disease progressed.

"Oligodendroglioma and astrocytoma are distinct tumor types, despite sharing the IDH mutation. This study shows that differences that exist when the tumor is first detected can set the stage for what happens after it is treated," Varn said.

Some of the genetic changes in recurring tumors appeared to be associated with poorer outcomes. In astrocytomas, large-scale chromosomal abnormalities, including the duplication of entire sets of chromosomes and instances in which chromosomes broke apart and reassembled, were linked to shorter survival after recurrence. In oligodendrogliomas, some of the new genetic changes that emerged as the tumors recurred, including changes linked to uncontrolled cell growth, were also associated with poorer outcomes.

Toward treatments tailored to tumor evolution

In 2024, the FDA approved the IDH inhibitor vorasidenib for certain patients with these tumors, marking a major advance for the field. While this study focused on the changes tumors undergo after radiation and chemotherapy, its findings can be applied to better tailor treatment approaches to specific glioma types and to the genetic changes they are likely to acquire as they evolve over time.

"Our results and data sets provide a reference that helps understand how current and new therapies alter tumor behavior. Ultimately, we hope this will enable us to not just observe but to direct tumor behavior and make therapies more effective that way," said Roel Verhaak, Ph.D., vice chair for research and professor of neurosurgery at Yale School of Medicine.

Publication details

Roel Verhaak, Divergent genomic evolution in astrocytomas and oligodendrogliomas, Nature (2026). DOI: 10.1038/s41586-026-11150-x. www.nature.com/articles/s41586-026-11150-x

Journal information: Nature

Key medical concepts

AstrocytomaOligodendrogliomaTemozolomide

Clinical categories

OncologyNeurologyClinical genetics Provided by Jackson Laboratory Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: What happens when brain tumors return? International study tracks genetic changes behind recurring cancers (2026, October 14) retrieved 15 October 2026 from https://medicalxpress.com/news/2026-10-brain-tumors-international-tracks-genetic.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.